Prostate cancer · Oligorecurrent pelvic nodes · elective nodal RT
OLIGOPELVIS (GETUG-P07)
Can elective pelvic RT plus short-course ADT provide durable control in pelvic nodal oligorecurrence?
Prospective single-arm phase II; n=67; fewer than 6 pelvic nodal relapses; pelvic RT+6 months ADT.
Arms / design
Prospective single-arm phase II; n=67; fewer than 6 pelvic nodal relapses; pelvic RT+6 months ADT.
Outcome visualization · source-reported data
PFS at reported landmarks
Single-arm; no comparative HR
PFS at reported landmarks · reported measure A58% at 3 y
Additional reported measure39% at 5 y
These are different reported landmarks/measures, not comparative treatment arms.
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Five-year ADT-free survival was 64%. This is not a randomized ENRT-vs-INRT trial; values shown are different time landmarks.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/34247896/
Primary source
undefined